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Objective. The present study aims at reviewing the main publications on the use of macrolides as immunomodulators in patients
with noncystic ﬁbrosis bronchiectasis. Source of Data. The Medline database was our source of data for this research carried
out until June 2011, using the key words: macrolides and bronchiectasis, while searching for original articles and reviews.
Summary of Data. Seven clinical studies that evaluated the action of the macrolides in patients with bronchiectasis were found.
There was the sputum volume, reduction in pulmonary exacerbation frequency, and in the use of antimicrobial treatment, in
addition to pulmonary function improvement. Conclusions. Anti-inﬂammatory action and immunomodulatory eﬀects can be
attributed to macrolides when administered in low doses and on the long term. This use has been well established both in diﬀuse
panbronchiolitis and in cystic ﬁbrosis. Evidence indicates possible beneﬁts in bronchiectasis. Future studies are needed, though,
to establish the ideal dose and treatment duration and to understand the implications in the generation of microbial resistance.
“When patients have bacteria that are resistant to all antibiotics, prescribe erythromycin,
leave them on it for a long time, and they will do much better”
Dr. Harry Shwachman, 1950
1.Introduction
Macrolides have been known for their antimicrobial actions
since 1952 [1]. Their mechanism of action consists of in-
hibiting protein synthesis by linking to the 50S ribosomal
subunit of susceptible microorganisms [2]. Macrolides are
widely used to treat infections of soft tissues and of the
respiratory tract due to their eﬃcacy against Gram-negative
and Gram-positive bacteria, including intracellular germs
such as Chlamydia and Legionella [3–5].
They are considered safe and easily tolerable. Their main
side eﬀects are nausea, vomiting, diarrhea, and abdominal
pain, which become more evident when erythromycin
is used in place of the other macrolides [6]. Transitory
alteration of transaminases and association with ventricular
arrhythmias are typically rare [2].
Mounting evidence suggests that macrolide antibiotics
have both anti-inﬂammatory and immune-modulatory
properties and are thus beneﬁcial to chronic pulmonary
diseases such as diﬀuse panbronchiolitis, cystic ﬁbrosis,
asthma, and bronchiectasis. These properties were suspected
upon the realization that erythromycin decreased the need
for corticosteroids in asthma treatment [7].
It must be pointed out that immunemodulation is the
suppression of inﬂammation and immune hyperactivation
without causing immune depression (immunsuppression)
[8].
The anti-inﬂammatory eﬀects of macrolides were ini-
tially proved on patients with diﬀuse panbronchiolitis (DPB)
[9–15], a chronic inﬂammatory disease of the respiratory
bronchioles of undetermined cause, aﬀecting mostly Asians.
The main symptoms are chronic cough, purulent sputum,
dyspnoea, and sinobronchial syndrome. It is commonly
associated with chronic infection by Pseudomonas aeruginosa
and, if not treated, leads to high mortality rates due to
respiratory failure.
Historically, DPB used to evolve into respiratory insuﬃ-
ciency and death in half of the patients within ﬁve years after2 Pulmonary Medicine
diagnosis. After infection by P. aeruginosa,h o w e v e r ,o n l y8 %
would survive the 5-year time frame [15].
Kudoh [15] proved a decrease in symptoms, an improve-
ment in pulmonary function, and a reduction in sputum
volume and inﬂammatory factor levels, as well as a decrease
in infection rates, resulting in a signiﬁcant drop in disease-
related mortality with the use of macrolides.
A retrospective study carried out by the Research Group
of the Ministry of Health, Labor, and Welfare of Japan
showed a pronounced improvement in survival rate after
long-termuseofmacrolidesatlowdoses.The5-yearsurvival
rate before the treatment with macrolides was 63% in the
1970s, and 72% between 1980 and 1984. After the intro-
duction of erythromycin in 1985, this rate increased to 92%
(P<0.0001) [16].
Since then, erythromycin has been the recommended
choice of treatment upon diagnosis [15]. This therapeutic
success is attributed to anti-inﬂammatory and immunemod-
ulatory eﬀects whose mechanisms have yet to be established.
The beneﬁts of macrolides in the treatment of cys-
tic ﬁbrosis are plain to see [5, 17, 18]. Recent biblio-
graphical review by Yousef and Jaﬀe proves this beneﬁt
through the increase in FEV1 and the decrease in pul-
monary exacerbation [18]. The therapeutic success of azith-
romycin is attributed to the combination between the anti-
inﬂammatory and antieﬀective eﬀects of the drug.
The use of macrolides has been investigated in asthma
treatment [19–21]: a systematic review by Richeldi et al. [19]
in 2008 involving 7 studies, with 416 participants, compared
theuseofmacrolidesinasthmatotheuseofaplacebo.There
was no statistically signiﬁcant diﬀerence in the FEV1 values
(forced expiratory volume in one second). Nevertheless,
there was signiﬁcant improvement in the symptoms scale
and in the eosinophil count. The review concluded that the
existing data are insuﬃcient to support the systematized use
of macrolides in asthma.
1.1. Bronchiectasis. Bronchiectasis is a chronic pulmonary
disease with a diverse etiology, characterized by recurrent
respiratory infection and chronic inﬂammation, leading to
the destruction of the airways and pulmonary parenchyma.
The treatment of bronchiectasis is currently based on the
treatment of the underlying cause, on the prevention and
control of respiratory infections, as well as on respiratory
physiotherapy, and on surgical corrections, in more severe
cases [22].
Since 1997, several studies based on the knowledge
acquired for the treatment of DPB have sought to learn more
about the role of macrolides in bronchiectasis.
For the bibliographical research carried out until June
2011 with the use of the Medline database, we used the
key words “macrolides” and “bronchiectasis”, seeking orig-
inal papers and reviews. We found seven clinical studies
that evaluated the action of macrolides on patients with
bronchiectasis. Only two studies were randomized, placebo-
controlled, and double blind (Table 1).
Koh et al. in a randomized, double-blind, placebo-
controlled study with children at a mean age of 13.1
years (±2.6) with increased previous airway reactivity, using
roxithromycin 4mg/Kg twice a day for 12 weeks, evidenced a
reduction in airway reactivity after the methacholine chal-
lenge test, in addition to an improvement in sputum pu-
rulence. However, it did not show any diﬀerence in sputum
cellularity nor pulmonary function improvement when eval-
uating FEV1. The authors did not identify the roxithromycin
mechanism of action in reducing the airway reactivity, but
inferred anti-inﬂammatory or antimicrobial mechanisms.
However, no conclusion was achieved, and the authors could
not demonstrate the correlation between their ﬁndings and
the clinical improvement [23].
Tsang et al. [24] evaluated the pulmonary capacity and
sputum features in 21 adults with bronchiectasis after the
use of erythromycin 500mg twice a day for 8 weeks, in a
double-blind, placebo-controlled study. They observed sig-
niﬁcant improvement in FVC (forced vital capacity) and
FEV1 (P<0.05) and a reduction in the 24-h sputum
volume (P<0.05). Nevertheless, there was no signiﬁcant
diﬀerence in the presence of microorganisms or in the
presence of inﬂammatory products (IL-1α,I L - 8 ,T N F α,
leukotriene B4) in the sputum. Despite the small number
of patients and the short duration of the study, there was
an apparent reduction in pulmonary exacerbation frequency
in the treated group in comparison to the placebo group.
The mechanism of action of the drug is unknown, but it
is unlikely to be bactericidal in view of the low dosage and
poor tracheobronchial penetration. The authors believe that
macrolides are a disease-modifying treatment in noncystic
ﬁbrosis bronchiectasis. Nevertheless, they underscore the
importance of further studies in the ﬁeld to determine dose
response, appropriate duration of therapy, and criteria for
patient selection.
Davies and Wilson in an attempt to reduce pulmonary
exacerbation frequency in patients with noncystic ﬁbrosis
bronchiectasis, evaluated the pulmonary function and spu-
tum features of 39 adults with a mean age of 51.9 years
(±16.1), after treatment with azithromycin 500mg once
daily for 6 days, 250mg once daily for 6 days, then 250mg
on Monday, Wednesday, and Friday for at least 4 months,
and on average for 20 months. All patients had had at
least four pulmonary exacerbations in the previous year. A
total of 33 patients completed the 4 months of treatment
and presented lower pulmonary exacerbation frequency
with reduced need for oral (P<0.001) and intravenous
(P<0.001) antibiotics when compared to their previous
individual data. A pulmonary evaluation was carried out in
25 patients. Signiﬁcant improvement was observed for all
parameters (P = 0.01). Symptoms such as cough, fatigue,
exercise tolerance, wheezing, and dyspnoea were evaluated
using a 5-point scale. A signiﬁcant improvement in all of the
aspects evaluated was observed [25].
Cymbala et al. [26] investigated the pulmonary function
and exacerbation frequency in 11 patients with bronchiecta-
sis, after the use of azithromycin 500mg twice weekly for 6
months. Patients were randomized in order to be given the
usual treatment or the usual treatment plus azithromycin.
Pulmonary function remained steady throughout the study.
There was reduction in exacerbation incidence (P = 0.019)
and reduction in sputum volume (P = 0.005) duringPulmonary Medicine 3
Table 1: Macrolides in noncystic ﬁbrosis bronchiectasis.
Study Study design N Macrolide Age (years) End-point
Koh et al. [23]
Randomized,
double-blind,
placebo-controlled
25
Roxithromycin
4mg/kgtwicedaily
for 12 weeks
13.1 ± 2.6
(i) Reduction of sputum purulence
(P<0.005)
(ii) Reduction in airway
responsiveness after methacholine
challenge (P<0.01)
Tsang et al. [24]
Randomized,
double-blind,
placebo-controlled
21 Erythromycin 500mg
twice daily for 8 weeks 50 ± 15
(i) FEV1 and FVC improvement
(P<0.05)
(ii) Reduction of 24-h sputum volume
(P<0.05)
(iii) Reduction of the number of
exacerbations
Davies and
Wilson [25] Prospective open-label 39
Azithromycin 250mg,
thrice weekly for 4
months
51.9 ± 16.1
(i) Reduction of clinical exacerbations
with the use of oral and
intravenous antibiotics (P<0.001)
(ii) Pulmonary function improvement
(P<0.01)
Cymbala et al.
[26]
Randomized,
open-label, crossover 11
Azithromycin 500mg
twice weekly for 6
months
—
(i) Reduction in pulmonary
exacerbations
(ii) Reduction of sputum volume
Yalcin et al. [27] Randomized, controlled 34
Clarithromycin
15mg/kg/day for 3
months
13.1 ± 2.7
(i) Reduction in bronchial
inﬂammation (P<0.02)
(ii) Pulmonary function improvement
(FEF25–75%) P<0.015
(iii) Reduction of sputum volume
(P<0.0001)
Anwar et al. [28] Prospective open-label 56
Azithromycin 250mg,
thrice weekly for at
least 3 months
63 (±12.9)
(i) Reduction in pulmonary
exacerbations (P<0.001)
(ii) Reduction of microorganisms rates
in the sputum (P<0.005)
(iii) Reduction in the self-reported
sputum volume
(iv) FEV1 improvement (P<0.002)
Serisier et al.
[29] Prospective open-label 21
Erythromycin
250mg/day for 12
months
62.5 (±11)
(i) Reduction in pulmonary
exacerbations (P<0.0001)
(ii) Reduction of antibiotics use
(P<0.0001)
FEV1: forced expiratory volume in one second; FEF25–75%: maximal midexpiratory ﬂow; FVC: forced vital capacity.
the treatment and later at the control stage, which persists
after the interruption of the treatment (P = 0.028), when
compared to the individual data obtained 6 months prior to
the intervention. Patients reported a boost in energy and an
improved quality of life.
Yalcin et al., in a randomized and controlled study, eval-
u a t e d3 4c h i l d r e na g e db e t w e e n7a n d1 8( m e a na g e1 3 . 1±
2.7) with noncystic ﬁbrosis bronchiectasis, after 3 months
using clarithromycin at a dose of 15mg/Kg/day. The control
group was given supportive therapy only, whereas the study
group received supportive therapy and clarithromycin. The
presence of inﬂammatory mediators (IL8, TNFα, IL10) and
the bronchoalveolar lavage (BAL) cellularity were evaluated,
along with pulmonary function and sputum production. No
important side eﬀects were observed. The results evidenced
a signiﬁcant reduction in daily sputum production (P<
0.0001), improvement in FEF25–75% (P<0.015) but
not in the other spirometric parameters, in addition to
a reduction in cellularity, the number of neutrophils, and
in IL-8 levels, with increased macrophages ratios in BAL.
No alteration was observed in the IL10 and TNFα levels,
or in the rates of bacterial isolates throughout the study.
The presence of microorganisms stimulates the production
of TNFα by the bronchial epithelium. As there was no
alterationtobacterialgrowth,thereductioninIL-8levelsand
of neutrophils could be attributed to the anti-inﬂammatory
eﬀectofclaritromicina.TheisolatedimprovementinFEF25–
75% was attributed to the removal of bronchial obstruction
in the airways of small and medium caliber, probably
due to reduction in inﬂammation at the bronchial wall,
reductioninsecretiontothebronchiallumen,andinhibition
of cholinergic response in the airway smooth muscle.
Despite the randomization, there was signiﬁcant diﬀerence
in the inﬂammation severity between the groups before the
beginning of the study. Nonetheless, the fact that no control
with placebo was used and no quantitative culture of BAL4 Pulmonary Medicine
was performed may have impaired the validity of the study
[27].
Anwar et al. described the use of azithromycin 250mg
three times a week in 56 adults (mean age 63 ± 12.9
years) with noncystic ﬁbrosis bronchiectasis for at least 3
months, on an average of 9.1 months, in a prospective open
study. This study compared the exacerbation frequency, the
self-reported volume, and the microbiology of the sputum,
as well as pulmonary function. The results obtained were
compared to each patient’s data obtained 6 months before
the intervention. Pulmonary function was evaluated in
29 patients. The study evidenced a marked reduction in
pulmonary exacerbation frequency (P<0.001) and in the
number of positive sputum cultures (P<0.005); improve-
ment in FEV1 (P<0.002), without any improvement in
FVC. All patients produced at least 1 tablespoon (>15mL)
of sputum daily, and at the end of the study, they no longer
produced sputum [28].
SerisierandMartininaprospective,open,noncontrolled
study evaluated the exacerbation frequency and the use
of Erythromycin in 21 patients aged 62.5 years (±11) on
average, after the use of erythromycin 250mg/day for 12
months. A comparison was made to each patient’s individual
data obtained prior to the 12-month time frame of the study.
Areductioninthenumberofexacerbations(P<0.0001)was
detected, along with a reduction in the number of treatment
days with oral (P<0.0001) and intravenous (P<0.0078)
antimicrobial [29].
Recent British guidelines on nonﬁbrocystic bronchiec-
tasis acknowledge the macrolides’ possible immunemodu-
lating eﬀects and suggest that they may have a disease-
modifying activity, while emphasizing the need for further
studies on the subject before [22].
1.1.1. Possible Mechanisms of Action. To date, there is a
paucity of data exploring the mechanisms of action of mac-
rolides in bronchiectasic patients as its clinical eﬀectiveness
has only been recently shown. Most of the data in this issue
have been extrapolated from other chronic lung disease and
animal or cell models or in vitro systems [18].
1.1.2. Airway Condition in Chronic Inﬂammation. Diseases
characterized by chronic airway inﬂammation, such as dif-
fuse panbronchiolitis, asthma, chronic obstructive pulmo-
nary disease (COPD), cystic ﬁbrosis, and bronchiectasis,
often bring with them mucus hypersecretion, bronchial
hyperactivity, and chronic inﬂammation [30]. The process
involves neutrophil inﬂammation with high levels of inﬂam-
matory cytokines IL1, IL8, and TNFα [28]. The inﬂamma-
tion, along with harmful bacteria-generated substances, may
lead to notable tissue damage.
The authors suggest that the eﬀect of macrolides on the
improvement of chronic inﬂammatory conditions surpasses
its antimicrobial eﬀects, considering that in all the studies
these drugs were administered in low doses, in which they
would not present bactericidal or bacteriostatic eﬀect [27].
It is believed that macrolides exert anti-inﬂammatory
and immunomodulatory eﬀects through the following
mechanisms [31].
(1).EﬀectonA irwa ysM ucus. Studiessuggestthatmacrolides
reduce expectoration by inhibiting the synthesis of mucus
proteins, such as mucin, by modulating gene expression, and
by inhibiting chloride channels in the epithelial cells. It is
believedthattheyactinthemucociliaryclearanceandmucus
viscosity, although these ﬁndings have yet to be explained
[31].
(2).EﬀectsonBacteria. Gram-negativebacteriasuchasPseu-
domonas aeruginosa produce an alginate bioﬁlm with pro-
tective action against phagocytosis and antimicrobial agents.
Infection starts with the adhesion of the host cells through
adhesins. The tissue is then damaged by the toxins and en-
zymes produced by the bacteria. Macrolides reduce the
bioﬁlm formation, the production of molecules responsible
for bacterial adhesion and mobility, and the secretion of
cytotoxic compounds by these bacteria [31].
(3). Immunomodulatory Eﬀect. Chronic inﬂammation is
characterized by the recruitment of neutrophils with the
release of lysosomal enzymes and the generation of reactive
oxygen compounds, resulting in tissue damage. Macrolides
reduce the quantity of neutrophils in the inﬂammation
site by decreasing molecular adhesion (E-selectin, ICAM-1),
integrins (CD11b/CD18), cytokines involved with chemo-
taxis (IL-8, IL-6, IL4, IL5), and TNFα.
Macrolides modulate phagocytosis indirectly reducing
neutrophil survival by accelerating their apoptosis. They
suppress the secretion of epithelial-derived neutrophil sur-
vival factors, as GM-CSF (granulocyte-macrophage colony-
stimulating factor).
Initially, macrolides improve the host’s defense through
neutrophil stimulation, production of proinﬂammatory cy-
tokines and mediators such as IL-1, IL-2, IL6, and GM-
CSF, and production of nitric oxide in order to contain the
infection [32]. However, continuous use attenuates chronic
inﬂammation, through the suppression of inﬂammatory
mediators (Il-8, eotaxin, TNFα and GM-CSF), thus limiting
tissue damage [33].
2. Conclusions
Despite the small number of studies shedding light on the
anti-inﬂammatory and immunomodulatory mechanisms of
the macrolides, there is strong evidence providing support to
the beneﬁt of using this type of drug for the long term and in
low doses to treat chronic inﬂammatory diseases, including
noncystic ﬁbrosis bronchiectasis.
The anti-inﬂammatory properties of macrolides are con-
solidated. The mechanisms of action, however, are still being
investigated.
Future studies are necessary to determine the beneﬁts of
macrolidesinthemanyinﬂammatorydiseasesoftheairways,
as well as the ideal dosage and duration of the treatment,
not to mention the impact of the development of bacterial
resistance.Pulmonary Medicine 5
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